Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation

Rationale: Galectin-3 (Gal-3) drives fibrosis during chronic lung injury, however, its role in acute lung injury (ALI) remains unknown. Effective pharmacological therapies available for ALI are limited; identifying novel concepts in treatment is essential. GB0139 is a Gal-3 inhibitor currently under...

Descripción completa

Detalles Bibliográficos
Autores principales: Humphries, Duncan C., Mills, Ross, Boz, Cecilia, McHugh, Brian J., Hirani, Nikhil, Rossi, Adriano G., Pedersen, Anders, Schambye, Hans T., Slack, Robert J., Leffler, Hakon, Nilsson, Ulf J., Wang, Wei, Sethi, Tariq, Mackinnon, Alison C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393216/
https://www.ncbi.nlm.nih.gov/pubmed/36003515
http://dx.doi.org/10.3389/fphar.2022.949264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393216/
https://www.ncbi.nlm.nih.gov/pubmed/36003515
http://dx.doi.org/10.3389/fphar.2022.949264

Ejemplares similares